Glycerin

Evidence Level: L5

Predicted Indications: 10

Glycerin
Glycerin: From Constipation to Cauda Equina Syndrome

## Pharmacist Assessment Report

Glycerin: From Constipation to Cauda Equina Syndrome

One-Sentence Summary

Glycerin is an osmotic agent originally used to treat constipation. The TxGNN model predicts it may be effective for cauda equina syndrome, but no clinical trials and no publications currently support this direction. This is a model-only prediction. Among the other top-ranked predictions, only open-angle glaucoma and irritable bowel syndrome have a plausible, though weakly supported, mechanistic link.

Quick Overview

Item	Content
Original Indication	Constipation disorder (from the TxGNN knowledge graph; no approved indication text in the Singapore licences)
Predicted New Indication	Cauda equina syndrome
TxGNN Prediction Score	99.60%
Evidence Level	L5
Singapore Market Status	✓ Marketed
Number of Registrations	3
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, glycerin is an osmotic agent. Its efficacy in constipation is established, but there is no recognised mechanistic link to compressive or inflammatory disease of the cauda equina.

The high score for cauda equina syndrome is a graph-based prediction only. No trials or literature were found to support it, so the prediction should be treated as a hypothesis, not a finding.

Other predictions have somewhat more plausible rationales:

Open-angle glaucoma (score 99.59%, L4): Oral or intravenous glycerin lowers intraocular pressure by raising plasma osmolarity. This is used mainly as a short-term rescue measure in acute angle-closure glaucoma. It is not a chronic therapy for open-angle disease, and systemic risks such as hyperglycaemia, dehydration and nausea limit long-term use.
Irritable bowel syndrome (score 99.49%, L4): Glycerin's laxative action may relieve constipation-predominant symptoms. The link rests on symptom overlap with the existing indication, and there is no controlled evidence in this condition.
Alopecia, hypotrichosis, alopecia areata, migraine and primary hereditary glaucoma: No supporting mechanism or clinical evidence was found.

Clinical Trial Evidence

Currently no related clinical trials registered for cauda equina syndrome. None were found for the other nine top-ranked predictions either.

Literature Evidence

For cauda equina syndrome, currently no related literature is available. Because the other predicted indications also have little or no evidence, the publications retrieved for them are summarised below; none provides direct efficacy evidence.

PMID	Year	Type	Journal	Key Findings
1614157	1992	Review	Klin Monbl Augenheilkd	Pathogenesis and treatment of primary angle-closure glaucoma; not open-angle disease (open-angle glaucoma)
32890110	2020	Case series	J Glaucoma	Glycerin-preserved donor corneoscleral patch grafts for glaucoma drainage devices; a tissue-preservation use, not a drug effect (open-angle glaucoma)
20872359	2011	Clinical study	Eur J Ophthalmol	Artificial tears with osmoprotection for ocular surface damage from glaucoma therapy (open-angle glaucoma)
3896179	1985	Double-blind trial	Arch Intern Med	Polysorbate 60 was ineffective for male pattern baldness; glycerin was used as the control (alopecia)
14555416	2003	Safety review	Int J Toxicol	Safety assessment of triacetin as a cosmetic ingredient (alopecia)
32227767	2020	Safety study	J Tradit Chin Med	Skin and eye safety of a bee venom hair essence in rabbits (alopecia)
14215532	1964	Historical review	JAMA	Commentary on irritable colon; no glycerin-specific data (irritable bowel syndrome)
29191058	2017	Preclinical	Drug Deliv	Berberine nanoemulsion formulation study; not a clinical IBS study (irritable bowel syndrome)
4666940	1972	Case series	Trans Am Acad Ophthalmol Otolaryngol	Glycerin injection for posterior epistaxis; not related to migraine (migraine disorder)

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN02748P	Lemon Sweet Purgative Syrup	Syrup	Not stated in the data compiled for this report
SIN02959P	Huachi Enema	Enema	Not stated in the data compiled for this report
SIN03514P	Minica S Enema	Enema	Not stated in the data compiled for this report

All three licences are valid single-ingredient products. Only syrup and enema forms are registered in Singapore.

Safety Considerations

Drug Interactions: The interaction screening returned 100 interacting drugs; 20 are shown in the data compiled for this report. Nearly all are rated Moderate, with one rated Minor (doxycycline). Examples include:

Abiraterone, tramadol, acetazolamide, hydrocortisone, salbutamol
Alfuzosin, hydrochlorothiazide, amiloride, amiodarone, amisulpride
Benazepril, anagrelide, propofol, apalutamide, apomorphine
Triamcinolone, arsenic trioxide, lumefantrine, asenapine

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction, cauda equina syndrome, has no clinical trials, no literature and no recognised mechanistic link, so the high score reflects only the graph model. The more plausible ideas, osmotic lowering of intraocular pressure and constipation-predominant IBS, are also unsupported by direct evidence and face practical limits.

To proceed, the following is needed:

Package insert warnings and contraindications from the Singapore regulator (HSA), which are currently missing and block safety screening
Mechanism of action data for glycerin
Controlled clinical evidence in a prioritised indication (for example, constipation-predominant IBS or short-term intraocular pressure control)
Assessment of route compatibility, since only syrup and enema forms are registered in Singapore
Review of the drug interactions and systemic risks (hyperglycaemia, dehydration) for any proposed new use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.